Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (NYSE: IQV) is frequently in the news as a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. News coverage about IQVIA highlights how the company combines high-quality health data, Healthcare-grade AI®, advanced analytics and technology to support clinical development and commercial decision-making.
On this page, readers can follow IQVIA news related to clinical research initiatives, technology launches and strategic partnerships. Recent announcements include a strategic collaboration with Amazon Web Services, under which AWS has been named IQVIA’s Preferred Agentic Cloud Provider to power a next-generation AI platform. Other news items describe the launch of IQVIA’s Clinical Trial Financial Suite, an AI-enabled platform for managing financial aspects of clinical trials, and partnerships with organizations such as Veeva Systems.
IQVIA news also covers topics such as quarterly financial results, leadership and board changes, awards for site relationships in clinical research and the expansion of clinical research networks. For example, the company reports on its Research & Development Solutions bookings and backlog, as well as its recognition with the WCG Pinnacle Award for Site Relationships in Professionalism and Communication.
Investors, researchers and industry professionals can use this news feed to monitor developments in IQVIA’s clinical research services, healthcare analytics capabilities, AI initiatives and collaborations across the life sciences ecosystem. Regularly reviewing IQVIA news can provide insight into how the company is applying data, analytics and technology to support the development and commercialization of medical treatments.
Summary not available.
Summary not available.
IQVIA Holdings Inc. (NYSE:IQV) will announce its fourth-quarter and full-year 2020 financial results on February 10, 2021, before the market opens. A conference call and webcast will be hosted by the management team at 9:00 a.m. ET on the same day. Interested parties must register in advance for the call. The earnings release and financial information will be available on the IQVIA Investor Relations website. IQVIA is a global leader in advanced analytics, technology solutions, and clinical research services within the life sciences industry, employing around 70,000 people across more than 100 countries.
IQVIA has partnered with Laboratoires Théa, a top independent eye care group in Europe, to implement its Orchestrated Customer Engagement (OCE) platform and the OneKey HCP/HCO reference database in over 22 markets. This collaboration aims to enhance Théa’s digital strategy and customer engagement, especially in the wake of changes prompted by the COVID-19 pandemic. The OCE platform integrates various functions to improve service delivery and relationships with healthcare professionals. IQVIA serves more than 125 life sciences companies with its innovative solutions.
Q2 Solutions, a clinical trial laboratory services organization formed from an IQVIA and Quest Diagnostics joint venture, has partnered with Adaptive Biotechnologies to provide advanced immune-driven research services. The collaboration introduces immunoSEQ® Assay and immunoSEQ® T-MAP™ COVID, enhancing testing capabilities for pharma clients, particularly in understanding immune responses related to COVID-19 and drug development. This partnership is poised to improve the drug development lifecycle through detailed immune response analytics.
Summary not available.
IQVIA (NYSE:IQV) has announced a collaboration with Servier to enhance its R&D clinical development processes through the SCORE program. This initiative aims to transform Servier's clinical trial applications and improve patient outcomes by utilizing optimized processes, data-driven insights, and innovative technology. Over the next two years, IQVIA will implement a robust program that leverages its expertise in R&D consulting, digital transformation, and technology solutions. The partnership is poised to address unmet medical needs and support Servier's ambitious growth plans.
IQVIA (NYSE: IQV) announced its support for the Real World Evidence Leadership Forum, uniting senior RWE executives from 18 pharmaceutical companies. This non-competitive group aims to address RWE challenges and enhance patient outcomes globally. Underlining the significance of real-world data, Dan Simpson of IQVIA stated that establishing trust in data usage is crucial. The forum's immediate focus includes fostering collaborative relationships between pharma and healthcare, promoting publications on trusted partnerships, and meeting biannually to tackle industry issues.
IQVIA announced that Zentiva is implementing its Orchestrated Customer Engagement (OCE) platform in 12 major markets. This partnership aims to enhance Zentiva's commercial operations and customer interactions. OCE will facilitate optimization of field processes and multi-channel marketing through AI/ML capabilities, benefiting sales and marketing teams. Paul Geymayer from Zentiva emphasized the importance of digitally enabling their teams to foster growth and efficiency.
IQVIA Holdings reported third-quarter 2020 revenue of $2,786 million, a slight increase of 0.6% year-over-year, with Technology & Analytics Solutions (TAS) revenue growing 10.2%. However, Research & Development Solutions (R&DS) revenue fell 4.5%, and Contract Sales & Medical Solutions (CSMS) dropped 13.9%. Adjusted EBITDA reached $604 million, up 1.9%. The company raised its 2020 revenue guidance to $11,100 - $11,250 million and provided a strong outlook for 2021, anticipating revenue between $12,300 million and $12,600 million.